美托洛尔联合非洛地平治疗社区高血压的临床疗效分析-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

美托洛尔联合非洛地平治疗社区高血压的临床疗效分析

Clinical analysis of metoprolol combined with felodipine in the treatment of hypertension in community

ES评分 0 浏览量：812 下载量：0

DOI	10.12208/j.ijcr.20230043
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2023, 7(1)
作者	阳大龙*,
作者单位	上海市嘉定区外冈镇社区卫生服务中心上海 ;
摘要	分析对社区内高血压患者使用美托洛尔联合非洛地平治疗的效果。方法从2020年1月-2022年1月区间内因高血压进入社区进行诊治的患者内随机选择80例展开实验，根据治疗药物对其进行组别分类，即实验与对照，每组内人数为40例。对照组内整体均接受非洛地平，实验组内整体均采取美托洛尔联合非洛地平，对比疗效。结果实验组血压改善程度显著对照组，P＜0.05。实验治疗有效率高于对照组，P＞0.05。结论对社区内高血压患者使用美托洛尔联合非洛地平治疗，可以稳定血压，提升疗效。
Abstract	Objective: To analyze the effect of metoprolol combined with felodipine on hypertension patients in the community. Methods: From January 2020 to January 2022, 80 patients who entered the community for diagnosis and treatment due to hypertension were randomly selected to carry out the experiment. According to the therapeutic drugs, they were classified into groups, that is, experiment and control. The number of patients in each group was 40. The control group received felodipine as a whole, and the experimental group received metoprolol combined with felodipine as a whole to compare the efficacy. Results: The improvement of blood pressure in the experimental group was significant in the control group (P<0.05). The effective rate of experimental treatment was higher than that of control group (P>0.05). Conclusion: Metoprolol combined with felodipine can stabilize blood pressure and improve curative effect in hypertensive patients in the community.
关键词	美托洛尔；非洛地平；社区高血压；临床疗效
KeyWord	Metoprolol; Felodipine; Hypertension In Community; Clinical Efficacy
基金项目
页码	140-142

参考文献
相关文献

[1] 刘刚. 探讨美托洛尔联合非洛地平治疗社区高血压的临床疗效
[J]. 中国社区医师,2021,37(30):60-61.
[2] 邵皎巍. 美托洛尔同非洛地平治疗社区高血压对血压水平的影响
[J]. 北方药学,2021,18(07):143-144.
[3] 惠宇平,乔蕾,张荣荣,田能. 美托洛尔联合非洛地平治疗社区高血压临床效果与安全性分析
[J]. 中国药物与临床,2021,21(07):1145-1146.
[4] 朱笑天,王艳哲,张秀云. 非洛地平联合美托洛尔对高血压患者血压与糖脂代谢指标的影响
[J]. 现代医学与健康研究电子杂志,2021,5(03):135-137.
[5] 郭小婷,徐华,韩晓红. 非洛地平缓释片联合美托洛尔治疗原发性高血压合并心力衰竭的效果观察
[J]. 中国实用医刊,2020,47(21):98-101.
[6] 吕红霞. 非洛地平联合美托洛尔在基层医院高血压患者治疗中的应用效果
[J]. 中西医结合心血管病电子杂志,2020,8(22):41.
[7] 柴飞. 美托洛尔联合非洛地平治疗社区高血压患者的临床疗效
[J]. 中国社区医师,2020,36(19):12-13.
[8] 王月春. 美托洛尔非洛地平联合治疗社区高血压的临床有效性安全性分析
[J]. 临床医药文献电子杂志,2020,7(43):144+166.
[9] 苏振美,张晓红,李花,陆志雄,冯雪峰. 观察美托洛尔联合非洛地平治疗社区高血压的临床疗效
[J]. 中国社区医师,2020,36(12):74+76.
[10] 孙建花,陈羽嫣,薄其凤. 美托洛尔联合非洛地平治疗社区高血压的有效性及安全性研究
[J]. 中国社区医师,2020,36(08):60+62.
[11] Zhong Qi,Wu Hua-bing,Niu Qin-shan,Jia Ping-ping,Qin Qi-rong,Wang Xiao-dong,He Jia-liu,Yang Wan-jun,Huang Fen. Exposure to multiple metals and the risk of hypertension in adults: A prospective cohort study in a local area on the Yangtze River, China
[J]. Environment International,2021,153.
[12] Deng Yue,Li Shuangyue,Chen Zhenzhen,Wang Wenjie, Geng Bin,Cai Jun. Mdivi-1, a mitochondrial fission inhibitor, reduces angiotensin-II- induced hypertension by mediating VSMC phenotypic switch
[J]. Biomedicine amp; Pharmacotherapy,2021,140.
[13] Gu Yeqing,Dong Jun,Meng Ge,Zhang Qing,Liu Li,Wu Hongmei, Zhang Shunming,Wang Yawen,Zhang Tingjing, Wang Xuena,Sun Shaomei,Wang Xing,Jia Qiyu,Song Kun,Liu Qiang,Niu Kaijun. Handgrip strength as a predictor of incident hypertension in the middle-aged and older population: The TCLSIH cohort study
[J]. Maturitas, 2021,150.
[14] Madika Anne-Laure,MacDonald Conor James,Gelot Amandine, Hitier Sixtine,Mounier-Vehier Claire,Béraud Guillaume, Kvaskoff Marina,Boutron-Ruault Marie- Christine, Bonnet Fabrice. Hysterectomy, non-malignant gynecological diseases, and the risk of incident hypertension: The E3N prospective cohort
[J]. Maturitas, 2021,15

引用本文

阳大龙*. 美托洛尔联合非洛地平治疗社区高血压的临床疗效分析 [J]. 国际临床研究杂志. 2023; 7; (1). 140 - 142.

文献评论

相关学者

相关机构